Neurocrine Biosciences Target Price

See Neurocrine Biosciences's analyst price targets ($200) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$154.06

Average Target Price

$202.61

31.5% upside

23 analysts in the last 4 months

High: $230 | Low: $165

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-13	Bernstein	$218	41.5% upside
2026-08-13	Morgan Stanley	$182	18.1% upside
2026-08-13	Deutsche Bank	$165	7.1% upside
2026-08-03	Wedbush	$194	25.9% upside
2026-08-03	H.C. WainwrightAndrew Fein	$215	39.6% upside
2026-08-03	Canaccord GenuitySumant Kulkarni	$210	36.3% upside
2026-07-31	Morgan Stanley	$196	27.2% upside
2026-07-31	Deutsche BankDavid Hoang	$190	23.3% upside
2026-07-31	Needham	$204	32.4% upside
2026-07-31	Piper SandlerGAAP EPS	$210	36.3% upside
2026-07-31	Robert W. BairdBrian Skorney	$225	46% upside
2026-07-31	Guggenheim	$222	44.1% upside
2026-07-21	Guggenheim	$200	29.8% upside
2026-07-17	Wells Fargo	$200	29.8% upside
2026-07-13	Truist Financial	$200	29.8% upside
2026-07-13	BMO Capital	$170	10.3% upside
2026-07-13	Wedbush	$185	20.1% upside
2026-07-07	RBC CapitalBrian Abrahams	$195	26.6% upside
2026-06-30	UBS	$208	35% upside
2026-06-02	Goldman SachsCorinne Johnson	$213	38.3% upside
2026-05-21	BernsteinJeffrey Walch	$221	43.5% upside
2026-05-06	Oppenheimer	$230	49.3% upside
2026-05-06	Piper Sandler	$207	34.4% upside
2026-04-06	Oppenheimer	$220	42.8% upside
2026-03-10	Cantor FitzgeraldJosh Schimmer	$195	26.6% upside
2026-02-23	Wolfe Research	$160	3.9% upside
2026-02-17	Truist FinancialDanielle Brill	$140	9.1% downside
2026-02-12	Needham	$185	20.1% upside
2026-02-12	RBC Capital	$177	14.9% upside
2026-02-12	Wedbush	$151	2% downside
2026-02-12	Morgan Stanley	$173	12.3% upside
2026-02-12	H.C. Wainwright	$192	24.6% upside
2026-01-23	UBS	$178	15.5% upside
2026-01-08	Truist Financial	$169	9.7% upside
2026-01-08	Morgan Stanley	$175	13.6% upside
2026-01-05	UBSAshwani Verma	$188	22% upside
2025-12-17	H.C. Wainwright	$198	28.5% upside
2025-12-11	Stifel Nicolaus	$188	22% upside
2025-12-08	RBC Capital	$180	16.8% upside
2025-10-29	Truist FinancialDanielle Brill	$172	11.6% upside
2025-10-29	UBS	$183	18.8% upside
2025-10-29	RBC Capital	$160	3.9% upside
2025-10-29	Mizuho Securities	$146	5.2% downside
2025-10-29	Stifel NicolausPaul Matteis	$183	18.8% upside
2025-10-29	BMO Capital	$147	4.6% downside
2025-10-29	NeedhamAmi Fadia	$184	19.4% upside
2025-10-29	Piper Sandler	$179	16.2% upside
2025-10-29	JefferiesAkash Tewari	$174	12.9% upside
2025-10-20	Morgan Stanley	$168	9% upside
2025-10-09	UBSAshwani Verma	$195	26.6% upside

Neurocrine Biosciences (NBIX) FAQ

Neurocrine Biosciences (NBIX) currently reports a target price of $200. Use the charts on this page to explore Neurocrine Biosciences's target price history and peer comparisons.

Analysts' average 12-month price target for Neurocrine Biosciences is $200, about 31.5% upside from the current share price of $154.06. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $200, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On target price, it currently shows $200. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.